Skip to main content
SpringerLink
Log in

EMEA and GSK address findings from the D:A:D study

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. D:A:D Study Group.Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371: 1417-1426, No. 9622, 26 Apr 2008

  2. EMEA.Further data needed to determine risk of heart attack with abacavir. Media Release: 2 Apr 2008. Available from: URL: http://www.emea.europa.eu

  3. GlaxoSmithKline.GlaxoSmithKline statement - Lancet publication of D:A:D data. Media Release: 2 Apr 2008. Available from: URL: http://www.gsk.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

EMEA and GSK address findings from the D:A:D study. React. Wkly. 1197, 1 (2008). https://doi.org/10.2165/00128415-200811970-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200811970-00001

Keywords

Search

Navigation